The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.
 
Vera Gorbunova
Consulting or Advisory Role - Eisai; Pfizer
Speakers' Bureau - Eisai; Ipsen; Lilly; Novartis; Pfizer
 
Thaddeus Beck
No Relationships to Disclose
 
Ralf Hofheinz
No Relationships to Disclose
 
Pilar Garcia-Alfonso
No Relationships to Disclose
 
Marina Nechaeva
No Relationships to Disclose
 
Antonio Cubillo Gracian
No Relationships to Disclose
 
Laszlo Mangel
No Relationships to Disclose
 
Elena Elez
No Relationships to Disclose
 
Dustin A. Deming
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech/Roche; Novocure
Research Funding - Bristol-Myers Squibb (Inst); Merck
 
Ramesh K. Ramanathan
Honoraria - Insys Therapeutics; Novocure; Pharmacyclics
Consulting or Advisory Role - Cerulean Pharma; Insys Therapeutics; Novocure; Pharmacyclics
Research Funding - Abbvie (Inst); Berg Pharma (Inst); Boston Biomedical (Inst); Celgene (Inst); Ipsen (Inst); Merck/Schering Plough (Inst); Merrimack (Inst); Superlab Far East (Inst)
 
Alison Torres
No Relationships to Disclose
 
Danielle Marie Sullivan
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Philip B. Komarnitsky
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Jordan Berlin
Honoraria - genentech; Nestle health science
Consulting or Advisory Role - Aduro Biotech; BeiGene; Celgene; Cornerstone Pharmaceuticals; EMD Serono; ERYTECH Pharma; Exelixis; Five Prime Therapeutics; Genentech/Roche; Gritstone Bio; Karyopharm Therapeutics; Opsona Therapeutics; Pierre Fabre; Symphony Evolution
Research Funding - Abbvie (Inst); Bayer (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Loxo (Inst); Merrimack (Inst); Novartis (Inst); OncoMed (Inst); Pharmacyclics (Inst); Symphony Evolution (Inst); Taiho Pharmaceutical (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Celgene; EMD Serono; Genentech/Roche; Nestle health science
Other Relationship - AstraZeneca; Symphony Evolution